Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 11/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281986 | 0.88 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL31069846 | 0.88 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8599201 | 0.85 | LMNA (0.68) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3823883 | 0.84 | MAOB (0.62) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL27434060 | 0.81 | FFAR1 (0.52) | MAOBMAOARHEB | |
| SCHEMBL7778474 | 0.81 | MAOB (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2096058 | 0.81 | LMNA (0.61) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL22398821 | 0.80 | MAOB (0.54) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1550410 | 0.80 | MAOB (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2390178 | 0.79 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| CN-117730083-A | Pyrimidine compounds as MAP4K1 inhibitors | 格兰马克专业公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
| EP-3988540-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME WITH IMPROVED ORAL BIOAVAILABILITY AND THEIR USE AS MEDICAMENTS | The Regents of the University of California (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3129354-B1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME WITH IMPROVED ORAL BIOAVAILABILITY AND THEIR USE AS MEDICAMENTS | UNIV CALIFORNIA (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2001016120-A9 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6417212-B1 | PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS | ELI LILLY & COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001064677-A1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6071928-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME, LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-0912579-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001450-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
| US-5347050-A | Cardioselective adrenoreceptor blocking agents; prophylaxis and therapy for coronary diseases, glaucoma, migraine | BERTHOLD RICHARD (CH) | 1994-09-13 | — | — | US | disclosed |
| EP-0052072-B1 | 3-AMINOPROPOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ AG (CH) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | LMNA 4260/4885CYP1A2 3111/4885PTGS1 4620/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | LMNA 2435/4885CYP1A2 2895/4885PTGS1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.